A look of the major listed cell immunotherapy companies in China
The summer of 2017 is the start of the golden age for cell immunotherapy. Since the end of June, there is no shortage of attention in this red-hot market. On June 29th, Sanpower Group, the Chinese pharma giant, has announced its acquisition of Dendreon with $819 million. The core product of the latter is the …